{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T11:55:35Z","timestamp":1775908535656,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,11]]},"DOI":"10.7759\/cureus.106836","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T11:13:12Z","timestamp":1775905992000},"source":"Crossref","is-referenced-by-count":0,"title":["Inpatient Initiation of Cobenfy (Xanomeline-Trospium Chloride) During Acute Psychotic Decompensation in a Patient With Schizoaffective Disorder: A Case Report"],"prefix":"10.7759","author":[{"given":"Preston A","family":"Phommathep","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spencer","family":"Larson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Zanella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Snow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425787","article-title":"","year":"2022","unstructured":"Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision. American Psychiatric Association, Washington, DC; 2022. 10.1176\/appi.books.9780890425787"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2024.0785","article-title":"Efficacy and safety of xanomeline-trospium chloride in schizophrenia: a randomized clinical trial","volume":"81","author":"Kaul I","year":"2024","unstructured":"Kaul I, Sawchak S, Walling DP, et al.. Efficacy and safety of xanomeline-trospium chloride in schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2024, 81:749-56. 10.1001\/jamapsychiatry.2024.0785","journal-title":"JAMA Psychiatry"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20252","article-title":"Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis","volume":"14","author":"Vancampfort D","year":"2015","unstructured":"Vancampfort D, Stubbs B, Mitchell AJ, et al.. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry. 2015, 14:339-47. 10.1002\/wps.20252","journal-title":"World Psychiatry"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2016.16050503","article-title":"Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group consensus guidelines on diagnosis and terminology","volume":"174","author":"Howes OD","year":"2017","unstructured":"Howes OD, McCutcheon R, Agid O, et al.. Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017, 174:216-29. 10.1176\/appi.ajp.2016.16050503","journal-title":"Am J Psychiatry"},{"key":"ref5","unstructured":"Cobenfy. (2024). Accessed. March 1, 2026: https:\/\/www.cobenfy.com\/."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2007.09.009","article-title":"Muscarinic acetylcholine receptors as CNS drug targets","volume":"117","author":"Langmead CJ","year":"2008","unstructured":"Langmead CJ, Watson J, Reavill C. Muscarinic acetylcholine receptors as CNS drug targets. Pharmacol Ther. 2008, 117:232-43. 10.1016\/j.pharmthera.2007.09.009","journal-title":"Pharmacol Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2017.03.016","article-title":"Allosteric modulation of GPCRs: new insights and potential utility for treatment of schizophrenia and other CNS disorders","volume":"94","author":"Foster DJ","year":"2017","unstructured":"Foster DJ, Conn PJ. Allosteric modulation of GPCRs: new insights and potential utility for treatment of schizophrenia and other CNS disorders. Neuron. 2017, 94:431-46. 10.1016\/j.neuron.2017.03.016","journal-title":"Neuron"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.2007.55","article-title":"An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission","volume":"4","author":"Shirey JK","year":"2008","unstructured":"Shirey JK, Xiang Z, Orton D, et al.. An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission. Nat Chem Biol. 2008, 4:42-50. 10.1038\/nchembio.2007.55","journal-title":"Nat Chem Biol"},{"key":"ref9","unstructured":"FDA. Cobenfy (xanomeline and trospium chloride) prescribing information. (2024). Accessed: March 1, 2026: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/216158s000lbl.pdf."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1421554","article-title":"The potential of muscarinic M(1) and M(4) receptor activators for the treatment of cognitive impairment associated with schizophrenia","volume":"15","author":"Yohn SE","year":"2024","unstructured":"Yohn SE, Harvey PD, Brannan SK, Horan WP. The potential of muscarinic M(1) and M(4) receptor activators for the treatment of cognitive impairment associated with schizophrenia. Front Psychiatry. 2024, 15:1421554. 10.3389\/fpsyt.2024.1421554","journal-title":"Front Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2017.01.004","article-title":"Impaired tuning of neural ensembles and the pathophysiology of schizophrenia: a translational and computational neuroscience perspective","volume":"81","author":"Krystal JH","year":"2017","unstructured":"Krystal JH, Anticevic A, Yang GJ, Dragoi G, Driesen NR, Wang XJ, Murray JD. Impaired tuning of neural ensembles and the pathophysiology of schizophrenia: a translational and computational neuroscience perspective. Biol Psychiatry. 2017, 81:874-85. 10.1016\/j.biopsych.2017.01.004","journal-title":"Biol Psychiatry"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017015","article-title":"Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia","volume":"384","author":"Brannan SK","year":"2021","unstructured":"Brannan SK, Sawchak S, Miller AC, Lieberman JA, Paul SM, Breier A. Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N Engl J Med. 2021, 384:717-26. 10.1056\/NEJMoa2017015","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02190-6","article-title":"Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial","volume":"403","author":"Kaul I","year":"2024","unstructured":"Kaul I, Sawchak S, Correll CU, et al.. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial. Lancet. 2024, 403:160-70. 10.1016\/S0140-6736(23)02190-6","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2024.04.012","article-title":"Overcoming the barriers to identifying and managing treatment-resistant schizophrenia and to improving access to clozapine: a narrative review and recommendation for clinical practice","volume":"84","author":"Agid O","year":"2024","unstructured":"Agid O, Crespo-Facorro B, de Bartolomeis A, Fagiolini A, Howes OD, Sepp\u00e4l\u00e4 N, Correll CU. Overcoming the barriers to identifying and managing treatment-resistant schizophrenia and to improving access to clozapine: a narrative review and recommendation for clinical practice. Eur Neuropsychopharmacol. 2024, 84:35-47. 10.1016\/j.euroneuro.2024.04.012","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001763","article-title":"Improving clinical cognitive testing: report of the AAN Behavioral Neurology Section Workgroup","volume":"85","author":"Daffner KR","year":"2015","unstructured":"Daffner KR, Gale SA, Barrett AM, et al.. Improving clinical cognitive testing: report of the AAN Behavioral Neurology Section Workgroup. Neurology. 2015, 85:910-8. 10.1212\/WNL.0000000000001763","journal-title":"Neurology"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\"Mini-mental state\". a practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein MF","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. \"Mini-mental state\". a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975, 12:189-98. 10.1016\/0022-3956(75)90026-6","journal-title":"J Psychiatr Res"},{"key":"ref17","article-title":"Mental status examination in primary care","volume":"109","author":"Wiley AT","year":"2024","unstructured":"Wiley AT, Dreher JW, London JD. Mental status examination in primary care. Am Fam Physician. 2024, 109:51-60.","journal-title":"Am Fam Physician"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/478393-inpatient-initiation-of-cobenfy-xanomeline-trospium-chloride-during-acute-psychotic-decompensation-in-a-patient-with-schizoaffective-disorder-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T11:13:14Z","timestamp":1775905994000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/478393-inpatient-initiation-of-cobenfy-xanomeline-trospium-chloride-during-acute-psychotic-decompensation-in-a-patient-with-schizoaffective-disorder-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.106836","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,11]]}}}